OHIO DEPARTMENT OF MEDICAID
Pharmacy & Therapeutics Committee
Ohio Department of Medicaid, 50 West Town Street, Room C621
January 15th, 2020
10:00 A.M.

AGENDA

I. Call to Order
II. Introductions
III. Approval of October 2nd, 2019 Meeting Minutes
IV. Administrative Matters
   a. Conflict of Interest Statement
V. Department of Medicaid Update
VI. Interested Party Presentations
VII. Preferred Drug List (PDL) Proposal
   a. Katerzia™ (amlodipine suspension), Silvergate Pharmaceuticals, Calcium Channel Blockers-Dihydropyridine
   b. Nayzilam® (midazolam nasal spray), UCB, Anticonvulsants: First Generation
   c. Tosymra™ (sumatriptan nasal spray), Promius Pharma, CNS Agents: Anti-Migraine Agents – Serotonin 5-Ht1 Receptor Agonists – “Fast” Onset
   d. Drizalma Sprinkle™ (duloxetine DR), Sun Pharmaceutical Industries, CNS Agents, Antidepressants: Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
   e. Adhansia XR™ (methylphenidate ER cap), Adlon Therapeutics, CNS Agents: Attention Deficit Hyperactivity Disorder Agents – Long Acting, Solid
   g. Nourianz™ (istradefylline tab), Kyowa Kirin, CNS Agents: Parkinson’s Agents – Intermittent Treatment of Off Episodes
   h. Rybelsus® (semaglutide tab), Novo Nordisk, Endocrine Agents: Diabetes –Glucagon-Like Peptide-1 Receptor Agonists
   i. Rinvoq™ (upadacitinib ER tab), AbbVie, Immunomodulator Agents for Systemic Inflammatory Disease - Janus Kinase Inhibitor
   j. ProAir® Digihaler™ (albuterol DPI), Teva Respiratory, Respiratory Agents: Beta-Adrenergic, Short-Acting Metered Dose Inhalers or Other Devices
   k. Duaklir® Pressair® (aclidinium bromide and formoterol fumarate DPI), Circassia Pharmaceuticals, Respiratory Agents: Beta-Adrenergic-Muscarinic Combinations (LABA/LAMA)
VIII. Drug Class Announcements
    a. Respiratory Agents, Cystic Fibrosis
       • Kalydeco* (ivacaftor), Vertex Pharmaceuticals Inc.
       • Orkambi* (lumacaftor/ivacaftor), Vertex Pharmaceuticals Inc.
       • Symdeko* (tezacaftor/ivacaftor), Vertex Pharmaceuticals Inc.
       • Trikafta* (elecbacaftor/tezacaftor/ivacaftor and ivacaftor), Vertex Pharmaceuticals Inc.
IX. Other Business
   a. Pediatric Strengths of Harvoni™ (ledipasvir and sofosbuvir tab), Gilead Sciences, Infectious Disease Agents: Hepatitis C – Direct-Acting Antiviral
   b. Pediatric Strengths of Sovaldi® (sofosbuvir tab), Gilead Sciences, Infectious Disease Agents: Hepatitis C – Direct-Acting Antiviral
   c. Respiratory Category Revisions
   d. Endocrine: Diabetes Cardiovascular Disease Updates
   e. Future PDL Drug Class Reviews

X. 2020 Meeting Dates
   a. Proposed for Quarter 2 – Wednesday, April 8th, 2020
      • Discuss move to Wednesday, April 15th, 2020
   b. Proposed for Quarter 3 – Wednesday, July 8th, 2020
   c. Proposed for Quarter 4 – Wednesday, September 30th, 2020

XI. Adjournment